GlassScriptPhysician profile
Nicholas David Shuler
NPI 1790103513
$17,529.21
in general payments reported to CMS, 2019-2025
69 companies · $3,741 in 2025
The $3,741 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,728 · 2020: $902 · 2021: $2,635 · 2022: $2,976 · 2023: $2,515 · 2024: $3,031 · 2025: $3,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,837 · Education: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,836.80 |
| Education | $450.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,816.67 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $1,607.29 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $1,348.29 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $1,117.40 | 2021-2025 | |
| Gilead Sciences, INC. | $814.57 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $718.65 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| E.R. Squibb & Sons, L.L.C. | $621.45 | 2019-2025 | Opdivo, Opdualag |
| Celgene Corporation | $611.62 | 2019-2024 | Reblozyl |
| Pfizer INC. | $538.85 | 2022-2025 | |
| Incyte Corporation | $501.74 | 2019-2023 | Jakafi |
| Seagen INC. | $484.15 | 2021-2023 | Tukysa, Adcetris |
| Genentech USA, INC. | $464.25 | 2019-2025 | Phesgo, Tecentriq, Polivy |
| Foundation Medicine, INC. | $408.61 | 2021-2023 | |
| Amgen INC. | $388.41 | 2020-2023 | Kyprolis, Blincyto |
| Regeneron Healthcare Solutions, INC. | $361.89 | 2022-2025 | Libtayo |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $349.85 | 2020-2025 | |
| Eisai INC. | $349.81 | 2021-2025 | |
| Abbvie INC. | $341.66 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $274.89 | 2022-2024 | |
| Histosonics, INC. | $222.45 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $217.12 | 2020-2023 | Epkinly, Imbruvica |
| Lilly USA, LLC | $209.54 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Array Biopharma INC | $203.86 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Tersera Therapeutics LLC | $175.47 | 2021-2025 | Zoladex, Quzyttir, Xermelo |
| Daiichi Sankyo INC. | $174.63 | 2021-2025 | Enhertu, Datroway |
| Bayer Healthcare Pharmaceuticals INC. | $174.41 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $163.17 | 2020-2025 | Onivyde |
| Dova Pharmaceuticals | $161.69 | 2020-2021 | |
| Caris Mpi, INC. | $160.50 | 2025 | Mi Cancer Seek |
| Epizyme, INC. | $158.16 | 2020-2022 | |
| Taiho Oncology, INC. | $156.90 | 2022-2025 | |
| Exelixis INC. | $156.28 | 2019-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $154.29 | 2021-2025 | |
| Kyowa Kirin, INC. | $153.95 | 2020-2025 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.96 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $144.13 | 2022-2023 | Tecvayli, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $138.33 | 2022-2025 | Iclusig, Alunbrig |
| Kite Pharma, INC. | $126.63 | 2020-2025 | Yescarta |
| Sobi, INC | $82.50 | 2022-2025 | |
| Amag Pharmaceuticals, INC. | $81.71 | 2021-2022 | |
| Astellas Pharma US INC | $70.40 | 2021-2025 | Padcev, Vyloy |
| Rigel Pharmaceuticals, INC. | $65.44 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Legend Biotech USA INC. | $60.98 | 2025 | Carvykti |
| Puma Biotechnology, INC. | $58.21 | 2020-2023 | |
| Global Blood Therapeutics, INC. | $46.48 | 2021-2022 | |
| Stemline Therapeutics INC. | $45.33 | 2023-2024 | Orserdu |
| Coherus Oncology, INC. | $45.02 | 2024-2025 | Loqtorzi |
| Recordati_rare_diseases_inc. | $43.86 | 2025 | Enjaymo |
| Blueprint Medicines Corporation | $43.06 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $40.95 | 2024-2025 | Xpovio |
| Sumitomo Pharma America, INC. | $39.03 | 2024-2025 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $38.70 | 2021 | |
| G1 Therapeutics, INC. | $38.66 | 2022 | |
| Myovant Sciences INC. | $38.15 | 2021-2022 | |
| Tolmar, INC. | $37.35 | 2024-2025 | Rubraca, Eligard |
| Myriad Genetic Laboratories, INC. | $35.68 | 2021 | |
| Clovis Oncology, INC. | $34.96 | 2020 | |
| Boston Scientific Corporation | $34.63 | 2022 | |
| Agios Pharmaceuticals, INC. | $27.82 | 2025 | Pyrukynd |
| Pharmaessentia USA Corporation | $27.04 | 2025 | Besremi |
| Beigene USA, INC. | $25.16 | 2021 | |
| Pharmacosmos Therapeutics INC. | $22.19 | 2022 | |
| Springworks Therapeutics, INC. | $19.73 | 2024 | Ogsiveo |
| Pharmaand Gmbh | $19.39 | 2025 | Rubraca |
| Apellis Pharmaceuticals, INC. | $18.66 | 2023 | Empaveli |
| Shield Therapeutics INC | $18.13 | 2025 | |
| Alexion Pharmaceuticals, INC. | $16.74 | 2025 | Ultomiris |
| Helsinn Therapeutics (U.S.), INC. | $16.53 | 2019 | |
| Geron Corporation | $16.20 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Shuler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.